CLASS ACTION UPDATE for ABBV, NTRA and OSCR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you

ABBV Shareholders Click Here: https://www.zlk.com/pslra-1/abbvie-inc-loss-submission-form?prid=27475&wire=1
NTRA Shareholders Click Here: https://www.zlk.com/pslra-1/natera-inc-loss-submission-form?prid=27475&wire=1
OSCR Shareholders Click Here: https://www.zlk.com/pslra-1/oscar-health-inc-loss-submission-form?prid=27475&wire=1

* ADDITIONAL INFORMATION BELOW *

ABBVie Inc. (NYSE:ABBV)

ABBV Lawsuit on behalf of: investors who purchased April 30, 2021 - August 31, 2021
Lead Plaintiff Deadline : June 6, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abbvie-inc-loss-submission-form?prid=27475&wire=1

According to the filed complaint, during the class period, AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

Natera, Inc. (NASDAQ:NTRA)

This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive.
Lead Plaintiff Deadline : June 27, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/natera-inc-loss-submission-form?prid=27475&wire=1

According to the filed complaint, (1) the Company's non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; (2) the Company's screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; (3) as a result of defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants' statements about the company's business, operations, and prospects lacked a reasonable basis.

Oscar Health, Inc. (NYSE:OSCR)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Oscar Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's March 2021 initial public offering.
Lead Plaintiff Deadline : July 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/oscar-health-inc-loss-submission-form?prid=27475&wire=1

According to the filed complaint, (1) Oscar was experiencing growing COVID-19 testing and treatment costs; (2) Oscar was experiencing growing net COVID costs; (3) Oscar would be negatively impacted by an unfavorable prior year Risk Adjustment Data Validation result relating to 2019 and 2020; (4) Oscar was on track to be negatively impacted by significant SEP membership growth; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP